Evidence map›Paper›PMID 36212481›Full record

ArticleFrontiers in oncology2022

Potential methylation-regulated genes and pathways in hepatocellular neoplasm, not otherwise specified.

Shengmei Zhou, Meng Li, Dejerianne Ostrow, David Ruble, Leo Mascarenhas, Bruce Pawel, Jonathan David Buckley, Timothy J Triche

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shengmei ZhouDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
Meng LiUSC Libraries Bioinformatics Services, University of Southern California, Los Angeles, CA, United States.
Dejerianne OstrowDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
David RubleDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
Leo MascarenhasKeck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Bruce PawelDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
Jonathan David BuckleyDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
Timothy J TricheDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
University of Southern California · USChildren's Hospital of Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The molecular basis of hepatocellular neoplasm, not otherwise specified (HCN-NOS) is unknown. We aimed to identify gene expression patterns, potential methylation-regulated genes and pathways that characterize the tumor, and its possible relationship to hepatoblastoma and hepatocellular carcinoma (HCC). Approach & Results: Parallel genome-wide profiling of gene expression (RNAseq) and DNA methylation (EPIC850) was performed on 4 pairs of pre-treatment HCN-NOS tumors and adjacent non-tumor controls. 2530 significantly differentially expressed genes (DEGs) were identified between tumors and controls. Many of these DEGs were associated with hepatoblastoma and/or HCC. Analysis Match in Ingenuity Pathway Analysis determined that the gene expression profile of HCN-NOS was unique but significantly similar to that of both hepatoblastoma and HCC. A total of 27,195 CpG sites (CpGs) were significantly differentially methylated (DM) between tumors and controls, with a global hypomethylation pattern and predominant CpG island hypermethylation in promotor regions. Aberrant DNA methylation predominated in Developmental Process and Molecular Function Regulator pathways. Embryonic stem cell pathways were significantly enriched. In total, 1055 aberrantly methylated (at CpGs) and differentially expressed genes were identified, including 25 upstream regulators and sixty-one potential CpG island methylation-regulated genes. Eight methylation-regulated genes ( Conclusions: HCN-NOS has a unique, stem-cell like gene expression and DNA methylation profile related to both hepatoblastoma and HCC but distinct therefrom. Further, 8 methylation-regulated genes associated with prognosis in HCC were identified.

Indexed as

EPIC850genome-wide DNA methylationhepatoblastomahepatocellular carcinomahepatocellular neoplasmnot otherwise specifiedRNAseq

Identifiers

PMID36212481
PMCPMC9532972
OpenAlexW4296736449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.